IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

The Role Of Nanotechnology In Modern Healthcare

Dr. Pisipati Aparna*, T.Sri Nikitha[1], U.Veda Sai Manogna[1], V.Satya Priya[1],S.Tejaswini[1] M. Raja Rajeswari[1], Dr. Pisipati Aparna[2]

1* Corresponding Author, 1 B. Pharmacy Students, NRI College of Pharmacy, Pothavarappadu, Agiripalli, Vijayawada,

2 Professor, Department of Pharmaceutics, NRI College of Pharmacy, Pothavarappadu, Agiripalli, Vijayawada

Abstract

Nanotechnology represents a groundbreaking field focused on manipulating materials at the nanoscale. Its integration with biology and medicine, termed nanobiotechnology, has transformed healthcare by enabling precise drug delivery, advanced diagnostics, and innovative therapeutic approaches. This review highlights the applications of nanotechnology in medicine, particularly in cancer therapy, cardiovascular diseases, and infectious diseases. It explores various drug delivery systems, such as liposomes, micelles, and dendrimers, which improve bioavailability, stability, and targeted drug efficacy. Furthermore, the challenges of scalability, regulatory issues, and potential toxicity are discussed. The future of nanotechnology lies in its potential for personalized medicine and vaccine development, positioning it as a cornerstone for advanced healthcare solutions.

Keywords: Nanomedicine, Nanobiotechnology, Nanocarriers,Liposomes, Targeted Therapy, Biocompatibility

INTRODUCTION:

Nanotechnology involves manipulating materials at the nanometer scale (one billionth of a meter) and has transformative applications across engineering, agriculture, construction, microelectronics, and especially healthcare. In medicine, nanotechnology—referred to as nanobiotechnology when combined with biology—offers potential for targeted, cost-effective treatments with minimal side effects.

Nanomedicine, a specialized branch, focuses on molecular-level interventions to treat diseases and repair tissues like bones and nerves. By deploying nanoparticles, this technology enables precise drug delivery, reducing harm to healthy tissues while enhancing therapeutic outcomes.

Future healthcare advancements will increasingly integrate nanotechnology with stem cells, genomics, and proteomics. However, ensuring safe, effective applications remains a major scientific challenge. Pharmacists and healthcare professionals will be pivotal in responsibly integrating these technologies into clinical practice, paving the way for more personalized and effective treatments[1].

Nanoscience involves studying the unique properties of materials at a scale of 1 to 100 nanometers (nm)[2,], while nanotechnology applies this research to develop or modify novel objects. The ability to manipulate materials at the atomic level enables the creation of nanomaterials. These materials possess distinctive optical, electrical, and magnetic properties at the nanoscale, making them valuable in fields like electronics and medicine. A key feature of nanomaterials is their large surface area-to-volume ratio, which distinguishes them from larger engineered objects. Unlike conventional materials, nanomaterials are governed by the principles of quantum mechanics rather than classical physics and chemistry. In essence, nanotechnology is the engineering of functional objects and systems at the molecular or atomic scale[3].

Nanotechnology has significantly impacted almost every industry, offering products that are better-built, safer, cleaner, longer-lasting, and smarter. These advancements span across medicine, communications, everyday products, agriculture, and more. Nanomaterials can be integrated into pre-existing products to enhance performance by imparting their unique properties. Alternatively, they can be used directly—such as nanocrystals and nanoparticles—to create advanced devices due to their distinctive nanoscale attributes. The potential benefits of nanomaterials are vast and could shape the future of nearly all industrial sectors[4].

Nanomaterials are already being used in various everyday products, such as sunscreens, cosmetics, sporting goods, tires, electronics, and more. In medicine, nanotechnology has revolutionized areas like diagnostics, imaging, and drug delivery. These technologies enable the mass production of products with enhanced functionality, lower costs, and more environmentally friendly manufacturing processes. This contributes to improved healthcare outcomes while minimizing the environmental impact of manufacturing[5].

Nanoparticles used as drug delivery systems are typically less than 100 nanometers in at least one dimension and are composed of various biodegradable materials such as natural or synthetic polymers, lipids, or metals. Due to their small size, nanoparticles are taken up by cells more efficiently than larger molecules, making them highly effective as transport and delivery systems. For therapeutic purposes, drugs can either be incorporated into the particle matrix or attached to the surface of the particle. A successful drug delivery system must be capable of controlling the behavior of the drug once it enters the biological environment. Nanosystems with diverse compositions and biological properties have been extensively studied for their potential in drug and gene delivery applications[6,7,8].

An effective drug delivery approach involves designing nanosystems based on a thorough understanding of their interactions with the biological environment, the target cell population, cell-surface receptors, changes in receptors during disease progression, and the mechanisms and sites of drug action. This also includes factors like drug retention, the necessity for multiple drug administrations, molecular mechanisms, and the disease's pathobiology. Furthermore, understanding the barriers to drug effectiveness—such as the stability of therapeutic agents in the cellular environment—is crucial. Reduced drug efficacy can result from instability within the cell, unavailability due to multiple targeting, or unfavorable chemical properties of the delivery molecules. Other contributing factors include genetic alterations in cell-surface receptors, the overexpression of efflux pumps, changes in signaling pathways as the disease progresses, or degradation of the drug[9].

For example, excessive DNA methylation as cancer progresses can cause certain anticancer drugs, such as doxorubicin and cisplatin, to fail. To improve the effectiveness of encapsulated drugs, it is essential to understand the mechanisms of cellular uptake, intracellular trafficking, retention, and protection from degradation[10].

Nanotechnology bridges the gap between biological and physical sciences by applying nanostructures and nanophases across various scientific fields[11], particularly in nanomedicine and nano-based drug delivery systems, where these particles hold significant interest. Nanomaterials are defined as materials with sizes ranging between 1 and 100 nanometers, influencing the advancement of nanomedicine in areas such as biosensors, microfluidics, drug delivery, microarray tests, and tissue engineering[12].

Nanotechnology uses therapeutic agents at the nanoscale to develop nanomedicines. The field of biomedicine, encompassing nanobiotechnology, drug delivery, biosensors, and tissue engineering, has been greatly advanced by the use of nanoparticles[13].

Pharmaceutical research has made significant strides in improving drug bioavailability, stability, and organ targeting. Pharmaceutical nanocarriers—tiny, versatile drug delivery systems—play a key role in these advancements. These nanocarriers encompass a variety of forms, including polymeric, lipidic, and inorganic nanoparticles, as well as liposomes, nanotubes, and nanocomplexes. By attaching ligands to their surfaces, these carriers enhance drug uptake and targeting[14].

This review provides an overview of essential characterization methods used for nanocarrier drug delivery systems (DDSs). It also addresses the limitations of these methods, as well as the regulatory and scalability challenges associated with manufacturing nanocarriers. They can be administered through various routes such as parenteral, nasal, topical, or oral[15,16].

HISTORY:

Petros and his colleague documented significant milestones in the development of nanotechnology. Their study highlights that the conjugation of polymers and drugs occurred in 1955 [17]. The first controlled-release polymer device was introduced in 1964, followed by the discovery of liposomes by Bangham in 1965. Albumin-based nanoparticles were reported in 1972, and liposome-based drug formulations emerged in 1973. The first micelle was formulated and approved in 1983. The FDA granted approval for the first controlled-release formulation in 1989, and the first polyethylene glycol (PEG) conjugated protein was marketed in 1990[18]

Types of Nanocarriers:

Micelles:

Micelles are sophisticated nanostructures formed by amphiphilic surfactant molecules, which possess both hydrophilic (water-attracting) and hydrophobic (water-repelling) properties. These molecules typically consist of lipids and other amphiphilic substances that, when introduced into an aqueous environment, spontaneously aggregate into spherical vesicles[19].

Structure and Formation:

Micelles self-assemble into a structure where the hydrophilic (polar) parts of the molecules face outward, interacting with the surrounding aqueous environment, while the hydrophobic (non-polar) parts cluster inward, shielded from the water. This arrangement creates a spherical structure with a hydrophobic core that can encapsulate hydrophobic substances, such as certain therapeutic agents, and a hydrophilic outer layer that stabilizes the micelle in aqueous solutions.

Size and Characteristics:

The diameter of micelles typically ranges from 10 to 100 nanometers (nm). Their size and ability to encapsulate both hydrophilic and hydrophobic substances make them highly versatile for various applications.

Applications:

1. Drug Delivery: Micelles are particularly valuable in drug delivery systems. By encapsulating hydrophobic drugs within their core, micelles enhance the solubility and stability of these drugs in aqueous environments. This improvement in solubility can lead to increased bioavailability, meaning that a greater proportion of the drug reaches its target site within the body.

2. Imaging Agents: Micelles can be used as imaging agents due to their ability to carry and deliver imaging contrast agents. The hydrophilic shell can be modified to include imaging agents that help visualize the distribution and accumulation of micelles in different tissues.

3. Therapeutic Agents: Beyond drug delivery, micelles can themselves serve as therapeutic agents. By incorporating therapeutic compounds or bioactive molecules into the micelle structure, it is possible to target specific cells or tissues, potentially providing targeted therapy with fewer side effects.

Advantages and Challenges:

Advantages:

- Enhanced Solubility: Micelles significantly improve the solubility of hydrophobic drugs, which is crucial for the delivery of many poorly soluble therapeutic agents.
- Controlled Release: Micelles can be engineered to provide controlled or sustained release of drugs, improving therapeutic efficacy and reducing the frequency of dosing.
- Targeted Delivery: Surface modifications of micelles can facilitate targeted drug delivery to specific cells or tissues, enhancing the therapeutic impact while minimizing off-target effects.

Challenges:

- Stability: Maintaining the stability of micelles in various physiological conditions can be challenging. Their structure must remain intact to ensure effective drug delivery and release.
- Scalability: The production and scaling up of micelle-based drug delivery systems must be carefully controlled to ensure consistency and quality.
- Regulatory Hurdles: The development and approval of micelle-based therapies involve navigating complex regulatory pathways to ensure safety and efficacy.

Liposomes:

Liposomes are spherical vesicles composed of lipid bilayers that can range in size from 30 nanometers (nm) to several microns. Their structure allows for the incorporation of both hydrophilic and hydrophobic therapeutic agents. Hydrophilic drugs are encapsulated within the aqueous core of the liposome, while hydrophobic drugs are embedded within the lipid bilayer[20].

Structure and Composition:

Liposomes are formed by arranging lipid molecules into a bilayer, creating a central aqueous compartment. This bilayer mimics cellular membranes, making liposomes versatile carriers for a variety of substances. The lipid composition of liposomes can be tailored to suit specific therapeutic needs, affecting properties such as stability, release rates, and interaction with biological tissues.

Applications:

1. Drug Delivery: Liposomes are widely used for delivering therapeutic agents, both hydrophilic and hydrophobic. This capability enhances the solubility and stability of drugs, allowing for more effective treatment. Liposomes can encapsulate a range of macromolecular drugs, including nucleic acids and crystalline metals.

2. Surface Modification: The surface of liposomes can be modified with various polymers, antibodies, and proteins to enhance targeting and delivery. These modifications enable liposomes to deliver drugs specifically to targeted cells or tissues, improving therapeutic efficacy and reducing side effects.

3. FDA-Approved Nanomedicine: An example of liposomal technology in clinical use is Poly(ethylene glycol) (PEG)-ylated liposomal doxorubicin, known as Doxil®. Doxil® was the first nanomedicine approved by the FDA. It is used for the treatment of breast cancer and enhances drug concentration in malignant effusions without requiring an increase in the overall dose. The PEGylation improves the circulation time and reduces the likelihood of the drug being cleared by the immune system.

Advantages:

Enhanced Drug Delivery: Liposomes improve the bioavailability of both hydrophilic and hydrophobic drugs. The ability to encapsulate diverse types of drugs within their structure helps in effective delivery and controlled release.

Targeted Therapy: By modifying the surface characteristics of liposomes, it is possible to target specific cells or tissues. This precision reduces off-target effects and enhances therapeutic outcomes.

Reduced Toxicity: The use of liposomes can help to reduce the systemic toxicity of drugs. For instance, liposomal formulations like Doxil® reduce the side effects associated with traditional chemotherapy by delivering the drug more selectively to cancer cells.

Challenges:

Stability: Maintaining the stability of liposomes in different physiological conditions and during storage can be challenging. Proper formulation and storage conditions are crucial for ensuring the effectiveness of liposomal drugs.

Cost: The development and production of liposome-based drugs can be expensive, which may affect their affordability and accessibility.

Regulatory Issues: Navigating the regulatory pathways for liposome-based drugs involves extensive testing and validation to ensure safety and efficacy, which can be time-consuming and complex.

Dendrimers:

Dendrimers are a unique class of macromolecules characterized by their highly branched, repetitive units that radiate from a central core. These structures feature a central core surrounded by layers of branching units, with the outermost surface adorned with various functional groups. These functional groups can be anionic (negatively charged), neutral, or cationic (positively charged), providing dendrimers with versatile chemical and physical properties[21].

Structure and Functionality:

Dendrimers are built through iterative synthesis, allowing for precise control over their size, shape, and surface characteristics. This branching structure results in a high surface area-to-volume ratio, enabling extensive modification and functionalization. The functional groups on the dendrimer surface can be tailored to achieve specific interactions, enhancing their utility in various applications.

Applications

1. Drug Delivery: Dendrimers can encapsulate therapeutic agents within their interior cavities or attach them to their surface functional groups. This dual capability enhances drug bioavailability and facilitates targeted drug delivery. The ability to customize dendrimer surfaces allows for improved interaction with biological systems, leading to enhanced therapeutic efficacy and reduced side effects.

2. Biodegradability: Dendrimers are designed to be biodegradable, which means they can break down into non-toxic components after fulfilling their role in drug delivery. This feature is crucial for minimizing long-term accumulation and potential toxicity in the body.

3. Imaging: Dendrimers are also used in imaging applications due to their transformable properties. Their high surface area and customizable nature allow for the incorporation of imaging agents, enhancing the resolution

and specificity of imaging techniques. This makes dendrimers valuable for diagnostic imaging and monitoring biological processes.

Advantages:

1. High Surface Area: The branched structure of dendrimers provides a large surface area for functionalization, allowing for the attachment of multiple therapeutic agents or imaging molecules.

2. Customizable Properties: The ability to modify the surface functional groups enables precise control over the dendrimer's interactions with biological systems, improving targeting and reducing off-target effects.

3. Biodegradability: Dendrimers are designed to degrade into non-toxic components, minimizing potential long-term toxicity and accumulation in the body.

Challenges:

1. Synthesis Complexity: The iterative process required to synthesize dendrimers can be complex and time-consuming, affecting scalability and production efficiency.

2. Cost: The sophisticated synthesis and functionalization of dendrimers can lead to high production costs, which may impact their affordability and widespread use.

3. Toxicity Concerns: While dendrimers are designed to be biodegradable, their potential toxicity and interactions with biological systems need thorough evaluation to ensure safety.

Carbon Nanotubes (CNTs):

CNT's are cylindrical nanostructures made from rolled-up sheets of single-layer carbon atoms arranged in a hexagonal lattice, known as graphene. They can be categorized into single-walled carbon nanotubes (SWCNTs) and multi-walled carbon nanotubes (MWCNTs), or sometimes even as several concentric nanotubes nested within each other[22].

Structure and Properties

1.Single-Walled Carbon Nanotubes (SWCNTs): These consist of a single layer of graphene rolled into a cylindrical shape. Their diameter typically ranges from 0.4 to 2 nm, but they can be several micrometers long. SWCNTs have unique electrical properties, often exhibiting metallic or semiconducting behavior depending on their chiral orientation.

2. Multi-Walled Carbon Nanotubes (MWCNTs): These consist of multiple concentric layers of graphene, resembling a series of nested cylinders. MWCNTs generally have larger diameters (up to 100 nm) and can be hundreds of micrometers long. They exhibit enhanced mechanical strength and greater surface area compared to SWCNTs.

3. Composition Variations: In some cases, CNTs are composed of several interlinked nanotubes, which can influence their mechanical and electronic properties. This variation allows for customization of CNTs to meet specific application requirements.

Applications

1. Drug Delivery: Carbon nanotubes' high external surface area allows for substantial drug loading capacities. Their cylindrical shape can encapsulate drugs within their hollow core or attach therapeutic agents to their surface. This feature makes CNTs effective carriers for targeted drug delivery and controlled release.

2. Imaging Contrast Agents: The unique optical and electronic properties of CNTs make them valuable as imaging contrast agents. Their ability to absorb and scatter light, combined with their high surface area, enhances imaging techniques such as fluorescence microscopy and Raman spectroscopy, providing clearer and more detailed images.

3. Biological Sensors: CNTs are used in biological sensors due to their high surface area and sensitivity. They can detect biological molecules or environmental changes through changes in their electrical or optical properties. This makes them useful for developing highly sensitive biosensors for detecting pathogens, toxins, or other biomolecules.

Advantages

1. High Surface Area: CNTs offer a high surface area-to-volume ratio, which enhances their capacity for drug loading and interaction with biological systems.

2. Versatile Properties: Their unique optical, mechanical, and electronic properties enable a wide range of applications, from drug delivery to imaging and sensing.

3. Mechanical Strength: CNTs exhibit remarkable mechanical strength and flexibility, making them suitable for use in advanced materials and composites.

Challenges

1. Biocompatibility: The biocompatibility of CNTs is a concern, as their interactions with biological systems can lead to potential toxicity. Thorough testing is required to ensure they are safe for use in medical applications.

2. Manufacturing Complexity: The synthesis of CNTs involves complex and costly processes. Producing high-quality, consistent CNTs on a large scale remains a challenge.

4. Regulatory Issues**:** The regulatory approval of CNT-based products requires extensive safety and efficacy testing, which can be time-consuming and costly.

Metallic Nanoparticles:

Metallic nanoparticles are nanoscale particles composed of metals, such as iron oxide and gold, with unique properties that make them valuable in various biomedical and technological applications[23].

Types and Structures:

1. Iron Oxide Nanoparticles:

- Structure: Iron oxide nanoparticles typically feature a magnetic core with a diameter ranging from 4 to 5 nanometers. This core is often coated with hydrophilic polymers, such as dextran or polyethylene glycol (PEG), to enhance biocompatibility and stability in aqueous environments.
- Magnetic Properties: The magnetic core imparts superparamagnetic properties to the nanoparticles, allowing them to be manipulated using external magnetic fields. This feature is particularly useful in imaging and therapeutic applications.

2. Gold Nanoparticles:

- Structure: Gold nanoparticles consist of a gold core surrounded by a monolayer of surface moieties. These moieties often include negative reactive groups that can be functionalized with various ligands for specific targeting.
- Surface Functionalization: The surface of gold nanoparticles can be modified with a variety of ligands, such as antibodies, peptides, or small molecules, enabling targeted delivery and interaction with specific cells or tissues.

Applications

1. Imaging Contrast Agents:

- Iron Oxide Nanoparticles: Due to their magnetic properties, iron oxide nanoparticles are used as contrast agents in magnetic resonance imaging (MRI). They enhance the contrast of images by altering the magnetic properties of surrounding tissues.
- Gold Nanoparticles: Gold nanoparticles are used in imaging techniques such as computed tomography (CT) and photoacoustic imaging. Their strong light absorption properties make them effective for enhancing image contrast.

2. Laser-Based Treatment:

- Gold Nanoparticles: Gold nanoparticles can absorb laser light and convert it into heat. This property is exploited in photothermal therapy, where nanoparticles are targeted to specific cells or tissues and then heated using a laser to induce localized damage or destruction. This method is used for treating cancer and other conditions.

Advantages

1. Versatility: Both iron oxide and gold nanoparticles offer versatility in their applications due to their unique physical and chemical properties.

2. High Surface Area: The large surface area of metallic nanoparticles allows for the attachment of multiple functional groups or drugs, improving their effectiveness in imaging and therapy.

3. Customizability: The surface of metallic nanoparticles can be modified to achieve specific interactions, such as targeting particular cells or enhancing imaging contrast.

Challenges

1. Toxicity: The potential toxicity of metallic nanoparticles, especially when used in high concentrations or over extended periods, needs to be thoroughly evaluated to ensure safety in clinical applications.

2. Stability: Maintaining the stability of metallic nanoparticles in biological environments is crucial for their effectiveness. Their interaction with biological fluids can affect their performance and safety.

3. Regulatory Approval: Navigating the regulatory landscape for metallic nanoparticles involves extensive testing to ensure they meet safety and efficacy standards before they can be used in medical applications.

Quantum Dots (QDs):

Quantum dots are nanoscale semiconductor particles with unique optical and electronic properties that make them highly valuable for various biomedical applications, including drug delivery and cellular imaging[24].

Structure and Composition

1. Core-Shell Structure: Quantum dots typically have a core-shell architecture. The core is made of semiconductor materials from the II-VI or III-V groups of the periodic table, such as cadmium selenide (CdSe) or indium phosphide (InP). This core is surrounded by a shell of another semiconductor material that helps to stabilize the core and enhance the optical properties of the quantum dots.

2. Size and Shape: Quantum dots range in size from 1 to 100 nanometers. Their small size allows them to interact with biological systems at the molecular level. The size of quantum dots can be precisely controlled during synthesis, which influences their optical properties, including emission wavelength.

Optical Properties

1. Fluorescence: Quantum dots exhibit strong fluorescence, meaning they emit light when excited by a light source. This fluorescence is highly stable and bright compared to conventional dyes, making QDs ideal for imaging applications.

2. Size-Tunable Emission: The emission color of quantum dots can be tuned by altering their size. Smaller quantum dots emit light at shorter wavelengths (blue), while larger quantum dots emit at longer wavelengths (red). This size-tuning ability allows for multiplexing, where multiple quantum dots with different emission colors can be used simultaneously to track various biological processes.

3. Photostability**:** Quantum dots are highly resistant to photobleaching, the process where fluorescent dyes lose their ability to emit light after prolonged exposure. This stability ensures that quantum dots provide consistent and reliable signals over extended periods.

Biomedical Applications

1. Drug Delivery: Quantum dots can be used in drug delivery systems due to their ability to be functionalized with various molecules. Drugs can be attached directly to the surface of quantum dots or encapsulated within them, allowing for targeted delivery and controlled release of therapeutic agents.

2. Cellular Imaging: The high brightness and stability of quantum dots make them excellent candidates for cellular imaging. They can be used to label and visualize specific cells or cellular components with high resolution.

3. Medical Imaging: Quantum dots enhance the quality of imaging techniques such as fluorescence microscopy and in vivo imaging.

Advantages

1. High Brightness: Quantum dots exhibit intense fluorescence, making them highly visible in imaging applications. This brightness improves the signal-to-noise ratio, leading to clearer images.

2. Long-Term Stability: Quantum dots are resistant to photobleaching, allowing for extended imaging sessions and more reliable data collection over time.

3. Customizable Surface Chemistry: The surface of quantum dots can be modified with various ligands, allowing for targeted delivery and specific interactions with biological molecules.

Challenges

1. Toxicity: Some quantum dots, particularly those containing heavy metals like cadmium, may pose toxicity risks. Ensuring the biocompatibility of quantum dots is crucial for their safe use in medical applications.

2. Complex Synthesis: The synthesis of quantum dots requires precise control over size, composition, and surface properties. The complexity of this process can affect scalability and cost.

3. Stability in Biological Environments: Maintaining the stability of quantum dots in biological environments, including preventing degradation or aggregation, is essential for their effectiveness in vivo.

Drug Delivery Methods:

The ultimate goal of drug administration is to ensure that the pharmaceutical substance reaches its intended target site and effectively carries out its therapeutic role. Drug delivery encompasses the methods and technologies used to administer drugs in a way that maximizes their therapeutic effects in humans or animals. This field has gained significant attention in pharmaceutical and medical sciences due to its potential to improve treatment outcomes.The primary objectives of drug delivery systems are to enhance the efficacy and safety of medications, minimize side effects, and improve patient adherence to treatment regimens. Various approaches are employed in drug delivery to achieve these goals, as outlined below.

Traditional Drug Delivery Systems (TDDS)

Historically, drugs have been administered through conventional methods such as tablets, capsules, and injections. These traditional drug delivery systems (TDDS) are designed to release medications into the bloodstream, resulting in systemic distribution throughout the body. Although these methods are effective, they have several limitations[25].

1. Systemic Distribution: Conventional drug delivery methods release drugs into the bloodstream, causing a broad distribution throughout the body. This systemic approach can lead to side effects as the drug affects both targeted and non-targeted tissues.

2. Limited Targeting: Traditional methods often lack the precision needed to target specific sites of action or diseased cells. This broad distribution can reduce the effectiveness of the treatment and increase the risk of adverse effects.

3. Common Methods:

- Oral: Drugs are ingested and absorbed through the digestive system.
- Topical: Medications are applied directly to the skin or mucous membranes.
- Trans-mucosal: Drugs are administered through mucous membranes, including nasal, buccal (inside the cheek), sublingual (under the tongue), vaginal, ocular (eye), and rectal routes.
- Parenteral: Drugs are delivered via injections directly into the body, bypassing the digestive system.
- Inhalation: Medications are administered through the respiratory tract, typically as aerosols or vapors.

4. Limitations:

- Drug Instability: Many drugs can degrade or lose efficacy due to instability during storage or within the body.
- Risk of Displacement: Systemically administered drugs may be displaced from their intended target site by other substances or physiological processes.
- Side Effects: Systemic delivery increases the likelihood of side effects as the drug interacts with various body systems.
- Slow Absorption: Some methods, particularly oral administration, can lead to slower drug absorption and delayed therapeutic effects.
- Enzymatic Deterioration: Oral drugs may be broken down by enzymes in the digestive system before they reach the bloodstream.

Advanced Drug Delivery System (ADDS):

Due to the limitations of traditional drug delivery systems (TDDS), ongoing innovations have focused on developing advanced drug delivery systems (ADDS) that address these shortcomings. ADDS aims to bypass traditional routes, delivering drugs directly to target sites in the precise amounts and at the optimal times [9].

Nanotechnology plays a crucial role in advancing ADDS. It allows for the reduction of drug dosage and dosing frequency while minimizing adverse effects. Key to this progress is the surface functionalization of nanoparticles, which is achieved through bioconjugation or passive adsorption of molecules onto their surfaces.

Moreover, traditional medications often do not utilize the most effective formulation for their specific needs. For instance, products containing proteins or nucleic acids require innovative delivery systems to enhance their effectiveness and protect them from degradation. The evolution towards more advanced drug delivery systems is crucial for optimizing the therapeutic potential of these complex molecules[26].

Targeted Drug Delivery:

Advanced Drug Delivery Systems (ADDS) are designed to enhance drug targeting by delivering medications directly to the disease site or specific area of action, thereby increasing the drug concentration in these targeted regions compared to non-target areas. This targeted approach can be achieved through various methods, such as encapsulating drugs in nanoparticles (NPs) that are engineered to accumulate in specific tissues or cells. By using NPs, targeted drug delivery can prolong and localize the drug's action, improving its bioavailability, biodistribution, and accumulation specifically in diseased areas, while minimizing exposure to healthy tissues. This targeted approach helps reduce toxicity and enhance therapeutic efficacy[27].

Targeted drug delivery systems can be categorized into two main types: active and passive targeting (see Figure 1).

- **Active Targeting:** This approach involves the use of ligands that interact with specific receptors on the surface of target cells. The ligands are designed to bind selectively to receptors that are overexpressed on diseased cells or tissues, allowing for precise delivery of the drug to the intended site.
- **Passive Targeting:** This method relies on the enhanced permeability and retention (EPR) effect. The EPR effect is based on the tendency of nanoparticles to accumulate in tumor tissues or inflamed areas due to their leaky vasculature and poor lymphatic drainage. This passive targeting leverages the physical characteristics of the disease site to achieve selective drug delivery.



Figure:1 targeted drug delivery and types

Controlled drug release:

Controlled release is a crucial application of nanotechnology in drug delivery, enabling the precise and gradual release of drugs from nanoparticles or other carriers over an extended period. This method ensures a sustained and consistent supply of medication at the target site, optimizing therapeutic effects and enhancing patient compliance.

To address this, some drugs are administered multiple times a day, such as 2–4 times daily. However, this approach complicates the treatment regimen and negatively impacts patient adherence. Controlled release systems aim to resolve these issues by providing a consistent release of the drug over time, aligning with therapeutic needs. This method achieves a zero-order release profile, where the drug concentration released remains constant, ensuring effective and manageable dosing throughout the treatment period[28].

Improvement in Drug Stability:

Drug stability refers to a drug's ability to maintain its physical, chemical, therapeutic, microbial, and toxicological properties throughout storage and usage. Ensuring drug stability is crucial for its effectiveness in reaching target sites and performing its pharmacological functions. The stability of a drug during storage depends on its formulation and constituent components, making it essential to consider stability during the drug design process.

Drug stability can be broadly categorized into five types:

- Chemical Stability: The drug's chemical composition remains unchanged.
- Physical Stability: The drug retains its physical properties, such as appearance and texture.
- Microbiological Stability: The drug resists microbial contamination or growth.
- Therapeutic Stability: The drug maintains its intended therapeutic effect.
- Toxicological Stability: The drug does not produce harmful or toxic effects over time.

Several factors influence drug stability, including temperature, light, pH, duration of storage, and packaging materials. Nanoparticles (NPs) have emerged as effective tools to enhance drug stability. By optimizing the size and surface properties of NPs, drug stability can be improved. However, it is equally important that the drug remains releasable at its target site; otherwise, the benefit of improved stability may not translate into better therapeutic outcomes[29].

Applications of Nanotechnology in Drug Delivery

By adjusting the size, surface properties, and materials of nanoparticles (NPs), they can be engineered into sophisticated systems capable of encapsulating both therapeutic and imaging agents.These customizations enhance the precision of drug delivery to specific sites, thereby reducing potential side effects. Nanotechnology has proven to be particularly valuable in treating diseases where traditional drug delivery methods have been ineffective, offering advanced solutions for more targeted and efficient treatments[30].

Treatment of Resistant Infectious Diseases

Treating infectious diseases has become progressively more difficult due to the adaptive nature of the pathogens responsible for these illnesses, which continuously evolve to evade treatment. Additionally, the problem of drug resistance is escalating as the misuse and overuse of antibiotics and other medications contribute to the development of resistant strains.

Addressing Antimalarial Drug Resistance

Malaria remains one of the leading causes of death in tropical and subtropical regions worldwide. Although numerous antimalarial drugs are available for treatment, their effectiveness often diminishes shortly after their introduction due to the development of drug resistance. This resistance results from the evolutionary adaptations of malaria parasites, which affect several metabolic pathways critical for drug efficacy.

Numerous studies have demonstrated the potential of nanotechnology in delivering antimalarials with promising results. Despite this, only a few of these innovations have advanced to clinical stages. Integrating nanotechnology with conventional antimalarial drugs—such as artemisinin and chloroquine—combines the active ingredients with advanced delivery systems, potentially overcoming resistance challenges and improving treatment efficacy[31].

Treatment of Bacterial Multi-Drug Resistance (MDR)

The indiscriminate use and misuse of antibiotics have led to a significant rise in multi-drug resistance (MDR), which is characterized by acquired resistance to at least one agent in three or more antimicrobial categories. This phenomenon severely hampers the ability to control bacterial infections and poses a serious global health threat. MDR arises through various mechanisms, including the efflux of drugs from target sites, enzymatic deactivation of antibiotics, and reduced permeability of bacterial cell walls.

This synergistic approach enhances treatment efficacy by leveraging the unique properties of NPs. NPs can disrupt MDR mechanisms through several actions: collapsing bacterial cell walls and membranes, generating reactive oxygen species (ROS) to damage bacterial cells, binding to and harming intracellular components, and destroying biofilm structures that protect bacteria. This combination therapy represents a paradigm shift in medicine, aiming to overcome the limitations of traditional antibiotics and provide more effective treatment options for MDR infections[32].

Cancer Therapy

Cancer remains one of the leading causes of death worldwide, accounting for approximately one in every six deaths globally in 2020, according to the World Health Organization (WHO). Cancer begins in a specific part of the body and can spread to other areas through a process known as metastasis. Early detection and treatment are crucial in the fight against cancer. Nanotechnology has emerged as a transformative tool in cancer diagnosis and therapy, offering several promising advancements.

Nanotechnology plays a significant role in improving cancer treatment outcomes by addressing the issue of anticancer drug resistance. Resistance often occurs due to mechanisms such as the efflux of drugs from the target site, which prevents the accumulation of pharmacologically effective doses. Nanotechnology helps overcome this challenge by enhancing the delivery and accumulation of anticancer agents at their intended sites thereby improving therapeutic efficacy.

Numerous studies have demonstrated that delivering anticancer agents using nanoparticles (NPs) can lead to enhanced therapeutic outcomes. NP-based drug delivery systems offer advantages such as improved pharmacokinetics, biocompatibility, targeted tumor delivery, and drug stability. These systems are designed to counteract drug resistance associated with conventional cancer chemotherapy, reducing associated toxicities and improving overall treatment effectiveness.

Additionally, Bai et al. reported that NP-mediated drug delivery to tumor neovasculature could overcome P-gp-mediated multidrug resistance, showing superior efficacy compared to traditional chemotherapy regimens. These findings underscore the potential of NP-based drug delivery systems in addressing the challenges of cancer treatment and enhancing therapeutic outcomes through targeted and efficient drug delivery[33].

Treatment of Cardiovascular Diseases

Cardiovascular diseases (CVDs) are the leading global cause of death, encompassing conditions such as hyperlipidemia, hypertension, myocardial infarction, stroke, and thrombosis. These chronic conditions often require long-term management, necessitating a focus on efficacy, safety, and patient compliance. Due to polypharmacy, where multiple drugs are prescribed, a single-dose formulation with sustained release is often preferred. Nanotechnology offers significant improvements in drug delivery for CVDs through targeted delivery and controlled release, which enhances drug efficacy, reduces side effects, and improves patient adherence.

For example, solid lipid nanoparticles (SLNs) have been used to enhance the bioavailability of drugs like carvedilol, an antihypertensive with poor solubility. Similarly, SLNs have improved the bioavailability of nitrendipine by four to five times. Such advancements in pharmacokinetics lead to better therapeutic outcomes for cardiovascular drugs[34].

Administration of Nutraceuticals

Nutraceuticals are food or food components with medicinal and health benefits, including antioxidant, anti-inflammatory, antimicrobial, and antineoplastic properties. Their effectiveness is often influenced by factors such as bioavailability, bioaccessibility, bioactivity, bioconversion, and bioequivalence. The size and composition of nutraceuticals impact their release and absorption in the gastrointestinal tract, affecting their bioavailability.

Nanoparticles (NPs) offer a solution to these challenges by enhancing the bioavailability of nutraceuticals. NPs, with their small size, surface charge, and high surface-to-volume ratio, protect bioactive compounds from degradation, improve solubility in aqueous environments, and facilitate better intestinal permeation and transcellular delivery .Various types of NPs, including lipid-based, surfactant-based, and biopolymeric, have been developed to effectively deliver both lipophilic and hydrophilic nutraceuticals, thereby improving their bioavailability [35].

Gene Therapy

Gene therapy faces significant challenges, particularly in overcoming drug resistance linked to genetic modifications. The successful delivery of genetic materials into cells is crucial for correcting genetic disorders or modifying cellular behavior. Nanotechnology has emerged as a promising solution for gene delivery, offering advantages such as improved circulation time, increased bioavailability, reduced immune system recognition, and precise gene regulation.

Nanoparticles used in gene delivery can include lipids, polymers, polypeptides, graphene-family nanomaterials, or inorganic materials like gold NPs. For instance, polyester-based and lipid NPs have been utilized to deliver short interfering RNAs (siRNAs) and plasmid DNA, respectively. The mRNA COVID-19 vaccines exemplify the use of lipid NPs for delivering messenger RNAs.These advancements highlight the potential of nanotechnology to revolutionize gene therapy by enhancing the efficacy and specificity of genetic material delivery[36].

Challenges of Nanotechnology

When designing and utilizing nanotechnology for drug delivery, several critical factors must be carefully considered. These include a thorough understanding of the components and their interactions, identifying key characteristics and how they affect performance, replicating these characteristics during manufacturing, ensuring sterile and scalable production, overcoming biological barriers to ensure nanoparticles reach and accumulate at the target site, and ensuring ease of storage and administration [37]. However, there are still significant challenges to the widespread use of nanotechnology, such as:

Toxicity and Biocompatibility

Nanoparticles (NPs) may exhibit toxic properties that are influenced by their composition, size, and surface characteristics. Ideally, drug-loaded NPs should interact with the host without causing adverse effects, ensuring biocompatibility. For example, protein-based NPs can lead to mild toxicities, such as hepatotoxicity, nephrotoxicity, cardiotoxicity, hypersensitivity reactions, aggregation, and instability. Similarly, lipid-based NPs may trigger cardiopulmonary distress, allergic responses, and anaphylactoid reactions, akin to protein-based NPs. On the other hand, metal-based NPs often affect growth and development systems, potentially causing genotoxicity, reproductive toxicity, DNA damage, and cellular inflammation.

Cost of Production

The cost of production for nanotechnology-based drug delivery systems encompasses the expenses related to research, development, manufacturing, and distribution. Several factors contribute to these costs, including the expense of materials, the complexity of the manufacturing process, and the stringent quality control required.However, ongoing research and advancements in manufacturing techniques are expected to gradually reduce these costs, potentially making nanotechnology-based treatments more accessible to a wider population. Despite these advancements, the high cost of production remains a challenge, tempering the full promise of nanotechnology in medicine[37].

Future Perspectives

Advancements in nanoparticle surface technology have significantly enhanced the potential of nanocarriers for future applications in targeted drug delivery. Nanotechnology's impact on medicine continues to grow, particularly in the areas of diagnosis, prevention, and treatment of diseases. A variety of nanocarrier formulations have already been approved for clinical use and are actively employed in treating and diagnosing several types of cancer. Furthermore, numerous other formulations are currently in various phases of clinical trials, demonstrating the vast potential of nanotechnology in healthcare.

Nanocarriers function by delivering drugs through several mechanisms, including passive targeting, active targeting, solubilization, and activated release. These systems enhance therapeutic efficacy by increasing drug accumulation at the targeted site while reducing the required dosage and minimizing systemic side effects. However, the clinical development of nanocarriers faces several key challenges, including biological barriers, large-scale manufacturing difficulties, biocompatibility concerns, safety, intellectual property issues, regulatory challenges, and the overall cost-efficiency compared to conventional treatments.

One promising future direction is the development of individualized therapeutic plans for nanomedicines, tailored to each patient's genetic profile and specific illness. This personalized approach could maximize the efficacy of nanocarriers and other nanomedicines, offering a more precise and effective treatment. Scientists are also exploring ways to simplify the complexity of nanocarriers and optimize their final dosage forms, ensuring they are practical and safe for human therapeutic use.

Nanotechnology has also created new opportunities to address challenges in immunology and vaccine development. The unique architectures of nanoparticle systems provide novel platforms for creating highly effective vaccines. For example, nanocarriers were instrumental in the development of vaccines against SARS-CoV-2, the virus responsible for COVID-19. Companies such as Moderna and BioNTech have successfully utilized nanocarriers to encapsulate mRNA that encodes the viral antigen. These vaccines, developed at unprecedented speed, demonstrated their effectiveness in large-scale phase III clinical trials, leading to emergency use authorizations and widespread deployment.

While nanocarriers show immense promise, challenges such as unwanted drug accumulation in non-target tissues—leading to toxicity—remain a critical concern. Therefore, it is essential that clinical studies focus on determining the biological distribution of nanoparticles after systemic administration to ensure safety.

Looking ahead, the future of nanotechnology in cancer therapy, particularly in solid tumor treatment, appears particularly bright. Researchers are now exploring more rational combinations of chemotherapeutic drugs and nanocarriers to further improve outcomes. Additionally, the development of nanotargeted radiopharmaceuticals for both the diagnosis and treatment of cancer holds great promise.

As nanomedicine continues to evolve, safety assessments will remain a priority. Furthermore, nanotechnology's potential impact on the global economy underscores the need for specific regulations. Given its rapidly expanding role in healthcare, the establishment of dedicated regulatory frameworks for nanotechnology will be essential to ensure the safety, efficacy, and equitable access to these advanced therapies.

Conclusion

Nanotechnology offers unparalleled opportunities to revolutionize medicine, particularly in drug delivery and disease treatment. By leveraging its ability to create precise, targeted, and efficient therapeutic systems, nanotechnology has shown immense potential in overcoming limitations posed by traditional medical approaches. Despite challenges such as cost, scalability, and toxicity, ongoing research and development continue to address these barriers. The future of nanotechnology in medicine lies in integrating these advancements with personalized treatment approaches, ensuring safer, more effective, and patient-specific healthcare solutions.

REFERENCE:

1. Santhi K, Dhanaraj SA, Joseph V, Ponnusankar S, Suresh B. A study on the preparation and anti-tumor efficacy of bovine serum albumin nanospheres containing 5- fluorouracil. Drug Dev Ind Pharm 2002; 28:1171- 1179.[CrossRef][Medline]
2. Drexler KE: Nanosystems: Molecular Machinery, Manufacturing, and Computation. John Wiley & Sons, New York, NY, 1989
3. Buzea C, Pacheco II and Robbie K: Nanomaterials and nanopar- ticles: Sources and toxicity. Biointerphases 2: MR17-MR71, 2007.
4. Allhoff F, Patrick L and Daniel M: What is Nanotechnology and Why Does it Matter? From Science to Ethics. John Wiley & Sons, pp3-5, 2010.
5. Mashaghi S, Jadidi T, Koenderink G and Mashaghi A: Lipid nanotechnology. Int J Mol Sci 14: 4242-4282, 2013.
6. Pison U, Welte T, Giersing M, Groneberg DA: Nanomedicine for respiratory diseases. Eu J Pharmacology 2006, 533:341-350.
7. Brannon-Peppase L, Blanchette JQ: Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004, 56(11):1649-1659.
8. Stylios GK, Giannoudis PV, Wan T: Applications of nanotechnologies in medical practice. Injury 2005, 36:S6-S13.
9. Groneberg DA, rabe KF, Fischer A: Novel concepts of neuropeptide-based therapy: Vasoactive intestinal polypeptide and its receptors. Eu J Pharmacology 2006, 533:182-194.
10. Grady WM: Epigenetic events in the colorectum and in colon cancer. Biochem Soc Trans 2005, 33:684-688
11. Liu Z, Tabakman S, Welsher K, Dai H. Carbon nanotubes in biology and medicine: in vitro and in vivo detection, imaging and drug delivery. Nano Res. 2009;2:85–120.
12. Arayne MS, Sultana N, Qureshi F. nanoparticles in delivery of cardiovas- cular drugs. Pak J Pharm Sci. 2007;20:340–8
13. Rudramurthy GR, Swamy MK, Sinniah UR, Ghasemzadeh A. Nano- particles: alternatives against drug-resistant pathogenic microbes. Molecules. 2016;21:836.
14. Pontes J.F., Grenha A. Multifunctional Nanocarriers for Lung Drug Delivery. *Nanomaterials.* 2020;10:183. doi: 10.3390/nano10020183. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
15. MaHam A., Tang Z., Wu H., Wang J., Lin Y. Protein-based nanomedicine platforms for drug delivery. *Small.* 2009;5:1706–1721. doi: 10.1002/smll.200801602. [PubMed] [CrossRef] [Google Scholar]
16. Harrington K.J. Phase II study of pegylated liposomal doxorubicin (Caelyx™) as induction chemotherapy for patients with squamous cell cancer of the head and neck. *Eur. J. Cancer.* 2001;37:2015–2022. doi: 10.1016/S0959-8049(01)00216-7. [PubMed] [CrossRef] [Google Scholar]
17. Katsuki S, Matoba T, Koga JI, Nakano K and Egashira K: Anti-inflammatory Nanomedicine for Cardiovascular Disease. Front Cardiovasc Med 4: 87, 2017
18. Lombardo D, Kiselev MA and Caccamo MT: Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine. J Nanomater 12: 1-26, 2019
19. Nune SK, Gunda P, Thallapally PK, Lin YY, Forrest ML and Berkland CJ: Nanoparticles for biomedical imaging. Expert Opin Drug Deliv 6: 1175-1194, 2009

20. Dai HJ, Hafner JH, Rinzler AG, Colbert DT and Smalley RE: Nanotubes as nanoprobes in scanning probe microscopy. Nature 384: 147-150, 1996
21. Mulder WJ, Strijkers GJ, van Tilborg GA, Cormode DP, Fayad ZA and Nicolay K: Nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging. Acc Chem Res 42: 904-914, 2009.
22. Probst CE, Zrazhevskiy P, Bagalkot V and Gao X: Quantum dots as a platform for nanoparticle drug delivery vehicle design. Adv Drug Deliv Rev 65: 703-718, 2013.
23. Sultana, A.; Zare, M.; Thomas, V.; Kumar, T.S.S.; Ramakrishna, S. Nano-Based Drug Delivery Systems: Conventional Drug Delivery Routes, Recent Developments and Future Prospects. Med. Drug Discov. 2022, 15, 100134. [CrossRef]
24. Vo, T.N.; Kasper, F.K.; Mikos, A.G. Strategies for Controlled Delivery of Growth Factors and Cells for Bone Regeneration. Adv. Drug Deliv. Rev. 2012, 64, 1292. [CrossRef]
25. Salahpour Anarjan, F. Active Targeting Drug Delivery Nanocarriers: Ligands. Nano-Struct. Nano-Objects 2019, 19, 100370. [CrossRef]
26. Lee, J.H.; Yeo, Y. Controlled Drug Release from Pharmaceutical Nanocarriers. Chem. Eng. Sci. 2015, 125, 75. [CrossRef] [PubMed]
27. Little, T.A. Toxicological Assessment of Degradation Products: Is It Relevant as a Complementary Approach during Stability Testing of Pharmaceuticals? J. Dev. Drugs 2014, 12, 18–24. [CrossRef]
28. Zare, H.; Ahmadi, S.; Ghasemi, A.; Ghanbari, M.; Rabiee, N.; Bagherzadeh, M.; Karimi, M.; Webster, T.J.; Hamblin, M.R.; Mostafavi, E. Carbon Nanotubes: Smart Drug/Gene Delivery Carriers. Int. J. Nanomed. 2021, 16, 1681–1706. [CrossRef]
29. Tsamesidis, I.; Lymperaki, E.; Egwu, C.O.; Pouroutzidou, G.K.; Kazeli, K.; Reybier, K.; Bourgeade-Delmas, S.; Valentin, A.; Kontonasaki, E. Effect of Silica Based Nanoparticles against Plasmodium Falciparum and Leishmania Infantum Parasites. J. Xenobiotics 2021, 11, 155–162.
30. Hetta, H.F.; Ramadan, Y.N.; Al-Harbi, A.I.; Ahmed, E.A.; Battah, B.; Abd Ellah, N.H.; Zanetti, S.; Donadu, M.G. Nanotechnology as a Promising Approach to Combat Multidrug Resistant Bacteria: A Comprehensive Review and Future Perspectives. Biomedicines 2023, 11, 413.
31. Bai, F.; Wang, C.; Lu, Q.; Zhao, M.; Ban, F.Q.; Yu, D.H.; Guan, Y.Y.; Luan, X.; Liu, Y.R.; Chen, H.Z.; et al. Nanoparticle-Mediated Drug Delivery to Tumor Neovasculature to Combat P-Gp Expressing Multidrug Resistant Cancer. Biomaterials 2013, 34, 6163–6174. [CrossRef] [PubMed]
32. Kumar, V.V.; Chandrasekar, D.; Ramakrishna, S.; Kishan, V.; Rao, Y.M.; Diwan, P.V. Development and Evaluation of Nitrendipine Loaded Solid Lipid Nanoparticles: Influence of Wax and Glyceride Lipids on Plasma Pharmacokinetics. Int. J. Pharm. 2007, 335, 167–175. [CrossRef] [PubMed]
33. Dima, C.; Assadpour, E.; Dima, S.; Jafari, S.M. Bioavailability of Nutraceuticals: Role of the Food Matrix, Processing Conditions, the Gastrointestinal Tract, and Nanodelivery Systems. Compr. Rev. Food Sci. Food Saf. 2020, 19, 954–994. [CrossRef] [PubMed]
34. Hou, X.; Zaks, T.; Langer, R.; Dong, Y. Lipid Nanoparticles for MRNA Delivery. Nat. Rev. Mater. 2021, 6, 1078–1094. [CrossRef] [PubMed]
35. Desai, N. Challenges in Development of Nanoparticle-Based Therapeutics. AAPS J. 2012, 14, 282. [CrossRef]
36. Li, X.; Wang, L.; Fan, Y.; Feng, Q.; Cui, F.Z. Biocompatibility and Toxicity of Nanoparticles and Nanotubes. J. Nanomater. 2012, 2012, 6. [CrossRef]
37. Pandey, G.; Jain, P. Assessing the Nanotechnology on the Grounds of Costs, Benefits, and Risks. Beni-Suef Univ. J. Basic Appl. Sci. 2020, 9, 63. [CrossRef]